Forbion related stories
All articles and analysis
Forbion in $450m pharma dealThe sale comes as Forbion is currently attempting to collect €150m for Fund III
- Forbion Capital to sell Santaris Pharma to Roche for up to $450 mln
Forbion Capital Partners has sold biopharmaceutical company Santaris Pharma A/S for $450 million to Roche. The deal is structured with an upfront cash payment of $250 million and additional contingent payments of up to $200 million based on achievement of certain milestones.
- Forbion Capital Partners' arGEN-X completes IPO
Clinical-stage biopharmaceutical company arGEN-X has completed its IPO. arGEN-X is a Forbion Capital Partners' portfolio company.
- Forbion Capital-backed uniQure completes IPO
Forbion Capital Partners-backed uniQure, which develops gene therapy products, has completed an initial public offering at a price of $17 per share on the NASDAQ. Jefferies and Leerink Partners acted as joint book-running managers and Piper Jaffray & Co. acted as lead manager for the IPO.
- Hookipa Biotech raises Series B led by Sofinnova and Forbion Capital
Hookipa Biotech has raised 20 million euros ($27.5 million) in a series B equity financing. Existing investors Sofinnova Partners and Forbion Capital Partners led the financing with three new investors Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners joining the round.
- Dutch first-timer reaches halfway mark on €150m fund
Netherlands-based Holland Private Equity has held a €77m interim close on its way to a target of €150m. The firm has also inked its first investment.
- Forbion strengthens investor base
Secondaries specialist Coller Capital, the principal backer of Forbion Capital Partners’ spin-out from ABN AMRO Capital, has moved to diversify the firm’s investor base by selling part of its stake to seven leading private equity investor groups.
- Forbion strengthens investor base(2)
Secondaries specialist Coller Capital, the principal backer of Forbion Capital Partners’ spin-out from ABN AMRO Capital, has moved to diversify the firm’s investor base by selling part of its stake to seven leading private equity investor groups.
- ABN AMRO spins out life sciences group
ABN AMRO Capital has spun out its life sciences venture arm, which operates a €200m life sciences fund, focused on the US and Europe.
- Forbion strengthens investor base
Secondaries specialist Coller Capital, the principal backer of Forbion Capital Partners’ spin-out from ABN AMRO Capital, has moved to diversify the firm’s investor base by selling part of its stake to seven leading private equity investor groups.